Patents by Inventor Matthew P. Greving

Matthew P. Greving has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122301
    Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.
    Type: Application
    Filed: December 4, 2024
    Publication date: April 17, 2025
    Inventors: Bing Li, Matthew P. Greving, Phung Tu Gip, Matt Lundberg, Mohan Srinivasan
  • Publication number: 20250066478
    Abstract: Provided herein are methods for making, and epitope-targeted, conditionally-activated, pro-drug, antibody, comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; one or more engineered epitope masks connected to a linker, wherein the linker comprises a peptide, a polymer, or a chemical-linker that is cleaveable in vivo at a target site by an enzyme or cleaved chemically, and wherein the one or more engineered epitope masks binds the epitope-specific antibody at the CDRs of the epitope-specific antibody; and wherein the one or more engineered epitope masks linked to the antibody via the linker, wherein the masks are conditionally bound to the CDRs of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 27, 2025
    Inventors: Matthew P. Greving, Alexander T. Taguchi, Cody Allen Moore
  • Patent number: 12215163
    Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 4, 2025
    Assignee: iBio, Inc.
    Inventors: Phung Tu Gip, Bing Li, Matthew P. Greving, Matt Lundberg, Mohan Srinivasan
  • Publication number: 20250019457
    Abstract: Provided herein are anti-Trop 2 antibodies or binding fragments thereof that bind Trop 2, e.g., human Trop 2. The anti-Trop 2 antibodies of the disclosure are useful for the treatment of proliferative disorders or cells that express Trop 2 or mutant Trop 2. Also provided herein are methods of use for the anti-Trop 2 antibodies or binding fragments thereof, as well as bi-valent or multi-valent anti-Trop 2 antibodies or binding fragments thereof that may form complexes that attract immune effectors or binding to other cells, such as, a second antibody, antigen-binding of the second antibody or fragment thereof; a target-binding protein, a cytokine; a lectin; or a toxin.
    Type: Application
    Filed: June 28, 2024
    Publication date: January 16, 2025
    Inventors: Dillon Phan, Cory Schwartz, Matthew P. Greving, Cody A. Moore, Tam Thi Thanh Phuong, Matthew Dent, Alexander T. Taguchi, Jiang Chen, Tom Sih-Yuan Hsu, Domyoung Kim, Martin Brenner
  • Publication number: 20240327515
    Abstract: Provided herein are novel human anti-CD3 antigen-binding polypeptides, treatments, nucleic acids, vectors, their preparation and their use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 3, 2024
    Inventors: Matthew P. Greving, Alexander Tomoaki Taguchi, Cody Allen Moore, Hari Hara S. Potula, Gao Liu
  • Publication number: 20240262929
    Abstract: Provided herein are anti-MUC16 antibodies or binding fragments thereof which bind the non-shed domain of MUC16. The anti-MUC16 antibodies or binding fragments thereof of the disclosure are useful for the treatment of cancer cells that shed the extracellular domain of MUC16.
    Type: Application
    Filed: February 5, 2024
    Publication date: August 8, 2024
    Inventors: Matthew P. Greving, Alexander Tomoaki Taguchi, Gao Liu, Hari Hara S. Potula, Cody Allen Moore
  • Publication number: 20240228637
    Abstract: Provided herein are anti-CCR8 antibodies or antigen binding fragment thereof, which bind to CCR8, wherein the CCR8 is a human CCR8 and the antibody does not bind human CCR4. The anti-CCR8 antibodies or antigen binding fragment of the disclosure are useful for the treatment of cancer diseases through the elimination of regulatory T cells. Also provided herein are methods of use for the anti-CCR8 antibodies or antigen binding fragment thereof.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 11, 2024
    Inventors: Dillon Phan, Tom Sih-Yuan Hsu, Tam Thi Thanh Phuong, Matthew P. Greving, Alexander Tomoaki Taguchi, Cory Schwartz, Jiang Chen, Gao Liu, Martin Brenner, Matthew William Dent, Cody Allen Moore
  • Publication number: 20240132604
    Abstract: Provided herein are anti-CCR8 antibodies or antigen binding fragment thereof, which bind to CCR8, wherein the CCR8 is a human CCR8 and the antibody does not bind human CCR4. The anti-CCR8 antibodies or antigen binding fragment of the disclosure are useful for the treatment of cancer diseases through the elimination of regulatory T cells. Also provided herein are methods of use for the anti-CCR8 antibodies or antigen binding fragment thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 25, 2024
    Inventors: Dillon Phan, Tom Sih-Yuan Hsu, Tam Thi Thanh Phuong, Matthew P. Greving, Alexander Tomoaki Taguchi, Cory Schwartz, Jiang Chen, Gao Liu, Martin Brenner, Matthew William Dent, Cody Allen Moore
  • Publication number: 20240117056
    Abstract: Provided herein are anti-EGFRvII antibodies and binding fragments thereof. The anti-EGFRvIII antibodies of the disclosure are useful for the treatment of cancers through, e.g., antibody-dependent cell cytotoxicity (ADCC). Also provided herein are methods of making and using the anti-EGFRvIII antibodies for the treatment of cancer, and polynucleotides that encode the same.
    Type: Application
    Filed: October 11, 2023
    Publication date: April 11, 2024
    Inventors: Dillon Phan, Tom Sih-Yuan Hsu, Matthew P. Greving, Martin Brenner, Tam Thi Thanh Phuong, Alexander Tomoaki Taguchi, Cory Schwartz, Gao Liu, Jiang Chen
  • Publication number: 20240092909
    Abstract: Provided herein are PD-1 agonist antibodies which bind PD-1. The PD-1 agonist antibodies of the disclosure are useful for the treatment of autoimmune and inflammatory diseases through the promotion of PD-1 signaling. Also provided herein are methods of use for the PD-1 agonist antibodies.
    Type: Application
    Filed: September 14, 2023
    Publication date: March 21, 2024
    Inventors: Matthew P. Greving, Gao Liu, Cody Allen Moore, Alexander Tomoaki Taguchi
  • Publication number: 20240096443
    Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of several reference protein structures, e.g., related antibody epitopes or protein binding sites. A Machine Learning (ML) model may be used to generate engineered polypeptides. After substituting target residues for corresponding residues in other reference structures in the same scaffold, the scaffolds with each set of target residues may be filtered by structural comparison to identify generalized scaffolds. Generalized scaffolds may be improved by screening libraries of polypeptides.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 21, 2024
    Inventors: Alexander T. Taguchi, Kevin Eduard Hauser, Cody Allen Moore, Matthew P. Greving
  • Publication number: 20230220102
    Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases.
    Type: Application
    Filed: May 13, 2021
    Publication date: July 13, 2023
    Inventors: Phung Tu GIP, Bing LI, Matthew P. GREVING, Matt LUNDBERG, Mohan SRINIVASAN
  • Publication number: 20230095685
    Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.
    Type: Application
    Filed: October 7, 2022
    Publication date: March 30, 2023
    Inventors: Matthew P. Greving, Alexander T. Taguchi, Kevin E. Hauser
  • Publication number: 20230016112
    Abstract: Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.
    Type: Application
    Filed: May 13, 2021
    Publication date: January 19, 2023
    Inventors: Matthew P. GREVING, Phung Tu GIP, Mohan SRINIVASAN, Andrew MORIN, Kevin Eduard HAUSER, Jordan R. WILLIS, Cody A. MOORE, Christian BARRETT, Alex T. TAGUCHI, Angeles ESTELLES
  • Patent number: 11545238
    Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 3, 2023
    Assignee: IBIO, INC.
    Inventors: Matthew P. Greving, Alexander T. Taguchi, Kevin E. Hauser
  • Publication number: 20220081472
    Abstract: Provided herein engineered peptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a reference target, and methods of selecting said engineered peptides. Further provided are methods of using the engineered peptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules.
    Type: Application
    Filed: November 29, 2021
    Publication date: March 17, 2022
    Inventors: Matthew P. GREVING, Kevin Eduard HAUSER, Andrew MORIN, Jordan R. WILLIS
  • Publication number: 20210166788
    Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.
    Type: Application
    Filed: December 1, 2020
    Publication date: June 3, 2021
    Inventors: Matthew P. GREVING, Alexander T. TAGUCHI, Kevin Eduard HAUSER
  • Publication number: 20080188618
    Abstract: The present invention provides novel porous copolymer films, compositions comprising such films, methods for making such films, and pre-polymerization mixes that can be used for making such films.
    Type: Application
    Filed: January 23, 2008
    Publication date: August 7, 2008
    Inventors: Matthew P. Greving, Neal Woodbury, Trent Northern